EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Taurine bolsters adoptive T cell therapy efficacy against hepatocellular carcinoma by reprogramming T cell function

Zhiming Zhang, Siwei Li, Mengjie Li, Li Gong, Xinyu Lu, Weikang Xu, An-An Chen, Yiyue Wang, Changsheng He, Guoheng Mo, Yuting Xie, Si-An Yue und 4 weitere

Cancer Immunology, Immunotherapy · 06.08.2026 · 75 (11)

DOI: 10.1007/s00262-026-04503-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 06.08.2026. Verfasst von Zhiming Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University; State Key Laboratory of Multi-organ Injury Prevention and Treatment…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Taurine, Liver Neoplasms, T-Lymphocytes. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive T cell therapy for advanced hepatocellular carcinoma (HCC) is limited by the immunosuppressive tumor microenvironment, which impairs T-cell function. Overcoming this immunosuppression and restoring T-cell functionality are crucial for improving therapeutic efficacy. Here, we investigated the role of taurine in regulating alpha-fetoprotein (AFP)-specific T-cell receptor-engineered T cells (TCR-T) function. Metabolomic profiling revealed that intracellular taurine levels declined during the early phase of T-cell activation, while expression of the taurine transporter SLC6A6 increased over time. In addition, taurine abundance was lower in HCC tissues than in normal liver tissues in vivo, suggesting that taurine availability is reduced during both T-cell activation and tumor progression. Functionally, taurine supplementation enhanced the cytotoxic activity, persistence, and intratumoral infiltration of AFP-specific TCR-T, while reducing exhaustion and apoptosis after repetitive tumor stimulation. In contrast, taurine-limited conditions impaired T-cell proliferation and survival, attenuated antitumor activity in vitro and in vivo, and promoted an exhaustion-prone phenotype. Taurine supplementation also partially restored the function of β-alanine-preconditioned T cells. Mechanistically, transcriptomic and proteomic analyses identified PI3K-AKT signaling as a key pathway associated with taurine-mediated T-cell regulation. Taurine-limited T cells showed reduced AKT phosphorylation and developed a metabolically stressed state characterized by increased mitochondrial respiration, glycolytic activity, reactive oxygen species production and mitochondrial structural abnormalities during activation. Together, these findings identify taurine availability as an important metabolic regulator of engineered T-cell fitness and support taurine-based metabolic conditioning as a potential strategy to improve TCR-T therapy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularTaurineLiver NeoplasmsT-LymphocytesImmunotherapy, AdoptiveHumansAnimalsMiceLymphocyte ActivationTaurine TransportersMetabolic ReprogrammingCell Line, Tumor

Stichwörter der Autor:innen

Adoptive T cellHepatocellular carcinomaSLC6A6Taurine

Substanzen

TaurineTaurine Transporters

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University; State Key Laboratory of Multi-organ Injury Prevention and Treatment; Key Laboratory of Infectious Diseases Research in South China (South…
  • Department of Gastroenterology, Integrative Microecology Clinical Center, Shenzhen Key Laboratory of Gastrointestinal Microbiota and Disease, Shenzhen Clinical Research Center for Digestive Disease, Shenzhen Hospital, S…
  • Department of General Practice, Shenzhen Hospital of Southern Medical University, Shenzhen, 518100, China.
  • Experimental Animal Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510220, China.
  • Translational and Clinical Research Institute, FMS, Newcastle University, Newcastle Upon Tyne, NE4 4HH, UK.

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Zhang, Z., Li, S., Li, M., Gong, L., Lu, X., Xu, W., Chen, A. A., Wang, Y., He, C., Mo, G., Xie, Y., Yue, S. A., Huang, L., Yang, C., Hou, J., & Zhu, W. (2026). Taurine bolsters adoptive T cell therapy efficacy against hepatocellular carcinoma by reprogramming T cell function. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04503-y

Vancouver

Zhang Z, Li S, Li M, Gong L, Lu X, Xu W, et al. Taurine bolsters adoptive T cell therapy efficacy against hepatocellular carcinoma by reprogramming T cell function. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04503-y

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhiming and Li, Siwei and Li, Mengjie and Gong, Li and Lu, Xinyu and Xu, Weikang and Chen, An-An and Wang, Yiyue and He, Changsheng and Mo, Guoheng and Xie, Yuting and Yue, Si-An and Huang, Lei and Yang, Chou and Hou, Jinlin and Zhu, Wei},
  title = {Taurine bolsters adoptive T cell therapy efficacy against hepatocellular carcinoma by reprogramming T cell function},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04503-y}
}
Kostenlos starten →